Short answer
Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Nurix announced fiscal-quarter results for the period ended May 31, 2026.
Nurix Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Nurix announced fiscal-quarter results for the period ended May 31, 2026
- Full financial details and management commentary are contained in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Roche collaboration: $700M upfront and up to $2.3B total payments for bexobrutideg, subject to closing conditions
- Development costs shared 40% Nurix and 60% Roche, with equal U.S. profit/loss sharing and tiered ex-U.S. royalties
- Bexobrutideg CLL data: 83% ORR and 22.1-month median progression-free survival in Phase 1a
- Phase 1b ORR reached 92.9% in BTK-treated, BCL2-naïve patients and 84.2% in BTK-naïve patients
- Cash and securities $443.5M at May 31, 2026, with pro forma cash approximately $1.14B including Roche upfront payment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nurix Therapeutics, Inc. 8-K filings
Get the next NRIX 8-K as it lands
Follow NRIX for push alerts, or ask the research agent what this filing means.